SCHEMBL3633711

SCHEMBL3633711

CCCNc1c(N)cccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
TSHR P16473 2/20 0.40
NR4A2 P43354 2/20 0.39
GAA P10253 3/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPK14 Q16539 1/20 0.39
CYP3A4 P08684 1/20 0.37
PIK3CA P42336 1/20 0.37
HTT P42858 1/20 0.36
APP P05067 1/20 0.35
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
ITGB1 P05556 1/20 0.34
ITGA4 P13612 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NLRP3 Q96P20 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7534755 0.86 MAPK14 (0.43) TSHRNR4A2GAAKDM4EMAPK14
SCHEMBL3786027 0.85 ALDH1A1 (0.47) ALDH1A1TSHRNR4A2GAAKDM4E
SCHEMBL307339 0.81 TSHR (0.40) ALDH1A1TSHRNR4A2GAAKDM4E
SCHEMBL2930867 0.81 ALDH1A1 (0.40) ALDH1A1TSHRNR4A2GAACYP3A4
Hydrochloric Acid SCHEMBL6270049 0.80 ALDH1A1 (0.39) ALDH1A1TSHRNR4A2GAACYP3A4
SCHEMBL11662825 0.79 MAPK14 (0.51) NR4A2GAAKDM4EMAPK14HTT
SCHEMBL3635788 0.79 CD44 (0.43) ALDH1A1TSHRGAAKDM4EMAPK14
SCHEMBL11508928 0.79 POLB (0.42) ALDH1A1TSHRNR4A2GAAKDM4E
SCHEMBL3875390 0.78 NPC1 (0.47) ALDH1A1TSHRKMT2A
SCHEMBL739146 0.78 SMN1; SMN2 (0.50) ALDH1A1KDM4EHTTBCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146969-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Novartis Ag (CH) 2010-01-27 EP disclosed
US-20090105266-A1 Organic compounds NOVARTIS AG (CH) 2009-04-23 US disclosed
WO-2008128968-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 NOVARTIS AG (CH) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105266-A1 Organic compounds SLCO2B1, SLCO1B1, SLCO1B3 ALDH1A1 45/4885TSHR 4209/4885NR4A2 1668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.